LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

TransMedics Group Inc

Open

SectorHealthcare

135.11 4.27

Overview

Share price change

24h

Current

Min

128.48

Max

135.62

Key metrics

By Trading Economics

Income

19M

26M

Sales

22M

144M

P/E

Sector Avg

86.671

51.198

EPS

0.7

Profit margin

17.892

Employees

728

EBITDA

20M

36M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-8.55% downside

Dividends

By Dow Jones

Next Earnings

30 Jul 2025

Market Stats

By TradingEconomics

Market Cap

1.1B

4.2B

Previous open

130.84

Previous close

135.11

News Sentiment

By Acuity

53%

47%

324 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

TransMedics Group Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 Sept 2024, 03:29 UTC

Top News

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

-8.55% downside

12 Months Forecast

Average 124 USD  -8.55%

High 146 USD

Low 80 USD

Based on 8 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

92.43 / 94.18Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

324 / 380 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.